News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EnzySurge Raises US$2 Million Proceeds Will be Used to Accelerate Market Launch of its Wound Care Product in 2008



1/23/2008 10:00:51 AM

ROSH HAAYIN, Israel, January 23 /PRNewswire/ -- EnzySurge Ltd. (EnzySurge), a provider of innovative solutions for chronic wound management, announced today that it expects to expand its recent US$2 million private investment round to US$3 million. With this capital, the Company intends to accelerate the FDA approval process and expand its marketing efforts, in order to launch its first product during the second half of 2008.

EnzySurge's DermaStream(TM) product line is based on its patented Continuous Streaming Therapy (CST(TM)) technology, a new comprehensive modality for chronic wound management. DermaStream allows for continuous streaming of multiple therapeutic solutions throughout all phases of wound treatment. The therapeutic solutions are optimized for wound debridement (removal of necrotic tissue), bacterial load reduction and enhanced healing.

Between three and four percent of the general population in developed countries suffers from non-healing, chronic wounds, caused by diabetes, venous insufficiency and age-related diseases. Patients with chronic wounds suffer from unremitting pain and recurring infections that sometimes require surgery (resulting in a significant decrease in quality of life). Current treatment typically requires hospitalization, is expensive and only partially effective. An estimated US$12 billion per year is currently spent on wound management worldwide, and the market is continually growing.

EnzySurge recently completed the first stage of a multi-centered clinical study with its unique enzymatic solution demonstrating safety, selective wound debridement and accelerated closure. "In light of encouraging clinical results, a positive regulatory environment and anticipated fast-track FDA approval, we expect to be able to increase our recent investment round from 2 to 3 million dollars," explained Amir Shiner, CEO of EnzySurge. "After four years of successful pre-clinical and clinical trials, we'll be ready to go to market. DermaStream was designed for safety, enhanced efficacy and ease-of-use - in hospital or at home."

About EnzySurge

EnzySurge Ltd. is a provider of innovative solutions for chronic wound management. Based on its patented Continuous Streaming Therapy(TM) (CST) and a series of optimized therapeutic solutions, its DermaStream(TM) product line delivers effective, affordable and user-friendly care throughout all phases of wound treatment: wound debridement (removal of necrotic tissue), bacterial load reduction and enhanced healing. DermaStream was designed for use in hospitals, clinics and at home.

EnzySurge combines a patented medical device with pioneering bio-technology research to deliver improved quality of life to chronic-wound patients, via enhanced healing and reduced treatment costs. For more information, visit http://www.enzysurge.com.

amirs@enzysurge.comboazg@enzysurge.com

CONTACT: PR Contacts: Amir Shiner, CEO, amirs@enzysurge.com,
+972-54-3030294; Boaz Gruener, Director of Marketing and Business
Development, boazg@enzysurge.com, +972-54-4563608


Read at BioSpace.com


comments powered by Disqus
EnzySurge
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES